Hospital General Universitario Gregorio Marañón, Rheumatology Department, Dr Esquerdo 46, 28007, Madrid, Spain.
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):407-14. doi: 10.1586/erp.13.24.
Rheumatoid arthritis (RA) is a chronic systemic disease that leads to increases in health system economic burden through direct and indirect costs, including chronic treatment, reduced productivity and premature mortality. Anti-TNF agents have represented a major advance in the treatment of RA. The most commonly used (adalimumab, etanercept and infliximab) have demonstrated their cost-effectiveness at label doses. However, physicians may need to adapt the treatment by increasing the dose when a drug is not effective enough or by reducing it when there is a sustained effectiveness. In a cross-sectional study conducted in our hospital in which information from RA patients treated with anti-TNF drugs under conventional and modified doses were collected, the authors analyzed the costs of the medication in order to estimate the mean patient-year cost, the annual costs related to clinical efficacy and the cost per responder patient to anti-TNF treatment when dosage modification is undertaken in daily clinical practice.
类风湿关节炎（RA）是一种慢性系统性疾病，通过直接和间接成本（包括慢性治疗、生产力下降和过早死亡）增加卫生系统的经济负担。抗 TNF 药物的治疗代表了 RA 治疗的重大进展。最常用的药物（阿达木单抗、依那西普和英夫利昔单抗）在标签剂量下已证明其具有成本效益。然而，当药物不够有效时，医生可能需要通过增加剂量来调整治疗，或者当药物持续有效时通过减少剂量来调整治疗。在我们医院进行的一项横断面研究中，收集了接受常规和改良剂量抗 TNF 药物治疗的 RA 患者的信息，作者分析了药物的成本，以估算平均患者年成本、与临床疗效相关的年度成本以及在日常临床实践中进行剂量调整时每个应答者患者的抗 TNF 治疗成本。
